Primary B Cell Cutaneous Lymphoma
This entry looks at primary B cell cutaneous lymphoma, one of the subtypes of lymphoma. 'Lymphoma' is an umbrella term that loosely refers to several dozen independent categorical types and subtypes of cancers of the lymphatic system.
B Cell Cutaneous Lymphoma
A cutaneous lymphoma refers to several subtypes of lymphoma that affect the skin. These subtypes include:
- Peripheral T cell lymphoma
- Cutaneous T cell lymphoma
- Mycosis fungoides
- Sezary syndrome
- Adult T cell leukemia-lymphoma
- Lymphomatoid granulomatosis
And of course there are a few more, including primary B cell cutaneous lymphoma, in which B cell lymphocytes in the skin become cancerous.
B Cell Cutaneous Lymphoma
Primary B cell cutaneous lymphoma is a non-Hodgkin's lymphoma the origin of which is in the skin (thus the term 'primary'). If the disease spread to the skin from a different primary site, it would be considered secondary B cell cutaneous lymphoma and therefore a systemic disease. This however is extremely rare; it is exceedingly more common for primary B cell cutaneous lymphoma.
There are a handful of subtypes of primary B cell cutaneous lymphoma. They are:
- Primary cutaneous follicle center cell lymphoma (indolent)
- Primary cutaneous marginal zone B cell lymphoma (indolent)
- Large B-cell lymphoma of the leg (intermediately aggressive)
B Cell Cutaneous Lymphoma Treatment
Initial treatment for lower-stage primary B cell cutaneous lymphoma will involve at least one or more of the following therapuetic options:
- Locoregional radiotherapy
- Excision (surgical removal)
- Observation (only for certain cases)
- Topical applications
B Cell Cutaneous Lymphoma Prognosis
In general, primary B cell cutaneous lymphoma has an excellent prognosis, with a high cure rate (around 90%) when the appropriate treatment option is used. Although prognosis is very good, recurrence is not uncommon.
Sources
- Cutaneous Lymphoma Foundation
- International Society for Cutaneous Lymphomas
- Holland, Kerry, ed. Hematology/Oncology Clinics of North America. Volume 17, Nr 6, December 2003. WB Saunders Company.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
